Skip to main content

Table 1 Clinical course, tumor size, and serum tumor markers

From: Intrahepatic cholangiocarcinoma coinciding with a liver metastasis from a rectal carcinoma: a case report

Months Clinical course Tumor size (CT) (mm) Tumor marker Evaluate the response to treatment
S2 S3 S5 S6 S8 CEA (ng/mL) CA19-9 (U/mL)
0 At diagnosis 16 12 12 7 8 6 2601  
1 Lower anterior rectal resection         
2 XELOX + Bmab (1st course)       45.9 22,751  
5 XELOX + Bmab (4th course) 18 0 0 0 0 5.4 515 PR
7 XELOX + Bmab (7th course)       4.4 166  
9 XELOX + Bmab (9th course)       4.4 873  
11 XELIRI + Bmab (1st course) 21 0 0 0 0 9.5 9027 SD
13 XELIRI + Bmab (4th course)       43.4 42,380 PD
14 Extended left hepatectomy 46 0 0 0 0    
16 Gemcitabine + TS-1       10.9 2345  
  1. Clinical course and data are summarized. As CA 19-9 level had been increased during the XELOX + Bmab therapy, we changed the regimen to XELIRI + Bmab